瑞爾集團(06639.HK):種植牙服務價格超預期
瑞爾集團(06639.HK)指,國家醫保局印發《關於開展口腔種植醫療服務收費和耗材價格專項治理的通知》,明確三級公立醫院單顆常規種植牙醫療服務部分的總價原則上不超過4,500元人民幣。對於符合特定條件的地區或醫療機構,價格放寬比例不超過20%,整體定價好於預期。
集團指,包括其在內的民營機構未受價格調控影響,仍按自主定價,有助於充分展現技術勞務和服務價值。
另外,集團早前公布擬進行股份回購,回購後的股份將用於2022年限制性股票計劃。該計劃有效期為10年,公司將通過受託人從市場上按照市場交易價購買現有股份,相關股份面值將不超過公司已發行股份的10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.